Search for stock quotes, financial statistics and more
Research Capital analyst Andre Uddin maintained a “Speculative Buy” rating and C$12.00 target pr... Read More
Research Capital’s Andre Uddin said August 13 he remains focused on Eupraxia Pharmaceuticals’ (E... Read More
Following results that have sent the stock northward, Research Capital analyst Andre Uddin remains b... Read More
Following the announcement of a new financing, Raymond James analyst Rahul Sarugaser has lowered his... Read More
Following the release of new data, Raymond James analyst Rahul Sarugaser remains bullish about Eupra... Read More
Share
Tweet
pin
Share